MedTrace Logo

SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

NCT06787183 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-03-03

No results posted yet for this study

Summary

To enhance the treatment efficacy of rectal cancer liver metastasis through a multidisciplinary approach of radiotherapy, immunotherapy, and chemotherapy, and to provide a new direction for the combination treatment strategy.

Conditions

  • Locally Advanced Rectal Cancer With Liver Metastases

Interventions

DRUG

Oxaliplatin

130mg/m2, d1, q3w, 2 cycles

DRUG

QL1706

5.0 mg/kg, q3w

RADIATION

Short course radiotherapy

CTV 25Gy/5Fx.

DRUG

Capecitabine

1000mg/m2, d1-14，bid, q3w, 2 cycles.

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2026-12-01
Completion
2029-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06787183 on ClinicalTrials.gov